up to date!

After the outbreak of the new crown pneumonia epidemic, China immediately deployed drug research and development tasks, organized a team of superior experts, and promoted the technical research and development of effective drugs and treatments around the needs of clinical treatment
.

The Xie Xiaoliang team of Peking University's Biomedical Frontier Center has made important progress in the research of neutralizing antibodies by using single-cell sequencing technology, and the drugs developed have been used in clinical treatment
.

Using single-cell sequencing technology, research and development personnel screened the antibody DXP604 from the plasma of recovered patients to the antibody DXP604, which has good neutralizing activity against the new coronavirus, to a large extent, avoiding the escape of the virus
.

Cao Yunlong, associate researcher of Peking University’s Center for Biomedical Frontiers: In order for viruses to enter human cells, they need to interact with receptors recognized by the human body.
This antibody is actually a hundred times stronger than viruses and human receptors.
It can be more powerful.
The earth binds to the virus, so it is actually a competitive relationship.
It takes all the opportunities for the virus to bind to the human receptor, so that the antibody can block the virus from entering the human body
.

Starting in February 2020, the scientific research team has been involved in the research and development of new crown drugs
.

Relying on the anti-epidemic scientific and technological work system, Beijing urgently organized an expert seminar and agreed to use DXP604 as a sympathetic medicine in Beijing Ditan Hospital
.

Up to now, 36 patients with sympathetic medications have been used urgently.
After the patients have used them, their antibody levels have been significantly increased, their respiratory symptoms have been significantly improved, their sense of taste and smell has been restored, and their lung progress has been significantly delayed or improved
.

Cao Yunlong, associate researcher of Peking University's Center for Biomedical Frontiers: Our characteristic is that the throughput is relatively high, the number of screenings is relatively large, and the speed of obtaining antibodies will be relatively faster
.